NTLA PDUFA Date: Lonvoguran ziclumeran Page updated November 5, 2026 · next FDA decision on the calendar · Data as of Nov 5, 2026 5:03 AM ET FDA decision (PDUFA) target Mar 10, 2027 · Intellia Therapeutics, Inc. · Hereditary angioedema
Key facts FDA PDUFA target date 2027-03-10
Drug / candidate Lonvoguran ziclumeran (lonvo-z)
Indication Hereditary angioedema
Company Intellia Therapeutics, Inc.
Market-cap tier Small
New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs .
See every 2027 PDUFA date → All March 2027 PDUFA dates → FAQ When is the NTLA PDUFA date? The FDA PDUFA target date for NTLA (Intellia Therapeutics, Inc.) is 2027-03-10 for Lonvoguran ziclumeran (lonvo-z). Dates are company/FDA-sourced and can slip. Verify against primary filings.
What is NTLA's drug Lonvoguran ziclumeran? Lonvoguran ziclumeran (lonvo-z) is Intellia Therapeutics, Inc.'s candidate under FDA review for Hereditary angioedema.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.